139 related articles for article (PubMed ID: 38219810)
41. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
42. EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets - a primer for academic researchers.
Sudlow R; Branson J; Friede T; Morgan D; Whately-Smith C
BMC Med Res Methodol; 2016 Jul; 16 Suppl 1(Suppl 1):73. PubMed ID: 27410386
[TBL] [Abstract][Full Text] [Related]
43. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
44. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
[TBL] [Abstract][Full Text] [Related]
45. New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
Lexchin J
PLoS One; 2023; 18(6):e0286802. PubMed ID: 37319240
[TBL] [Abstract][Full Text] [Related]
46. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
47. Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA.
Hiayev S; Shacham-Shmueli E; Berkovitch M; Weiss I; Ashkenazi S; Vexberg MH; Hershkowitz R; Gorelik E; Mayan H; Steinmetz Y; Yanai NB; Schlissel O; Azem M; Gutgold N; Shulman K; Divinsky M; Yarom N; Vishkautzan A; Ganzel C; Gatt ME; Arcavi L; Marom E; Uziely B; Zevin S; Meirow H; Luxenburg O; Ainbinder D
BMJ Open; 2023 May; 13(5):e067313. PubMed ID: 37142315
[TBL] [Abstract][Full Text] [Related]
48. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
49. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
50. Participant Recruitment From Low- and Middle-Income Countries for Pivotal Trials of Drugs Approved by the U.S. Food and Drug Administration : A Cross-Sectional Analysis.
Awan FA; Becker AB; Wang Y; Kimmelman J
Ann Intern Med; 2022 Dec; 175(12):1675-1684. PubMed ID: 36410007
[TBL] [Abstract][Full Text] [Related]
51. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
52. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
Morant AV; Jagalski V; Vestergaard HT
Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
[TBL] [Abstract][Full Text] [Related]
53. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study.
Zeitoun JD; Ross JS; Atal I; Vivot A; Downing NS; Baron G; Ravaud P
BMJ Open; 2017 Dec; 7(12):e018587. PubMed ID: 29273664
[TBL] [Abstract][Full Text] [Related]
54. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
55. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
56. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
[TBL] [Abstract][Full Text] [Related]
57. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
58. Noncommercial US Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.
Whitlock EP; Dunham KM; DiGioia K; Lazowick E; Gleason TC; Atkins D
JAMA Netw Open; 2019 Jan; 2(1):e187498. PubMed ID: 30681715
[TBL] [Abstract][Full Text] [Related]
59. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
60. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]